PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: Relation to environmental and genetic determinants

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 4, 1998, Pages 562-567

  Margaglione, Maurizio ^a   Cappucci, Giuseppe ^a   D'Addedda, Marina ^a   Colaizzo, Donatella ^a   Giuliani, Nicola ^a   Vecchione, Gennaro ^a   Mascolo, Giulio ^a   Grandone, Elvira ^a   Minno, Giovanni Di ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Angiotensin converting enzyme; Fibrinolytic activity; Gene variant; Plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALCOHOLISM; ALLELE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; ENVIRONMENTAL FACTOR; FEMALE; GENE DELETION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

EID: 0031979233     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.4.562     Document Type: Article

References (23)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med. 1992:326:242-250.
2. Kannell WB. Bishop lecture: contribution of the Framingham study to preventive cardiology. J Am Coll Cardiol. 1990:15:206-211.
3. Tuomilehto J, Kuulasmaa K. The WHO MONICA project: assessing CUD mortality and morbidity. Int J Epidemiol. 1989;18(suppl 1):S38-S45.
4. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
5. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Study. Lancet. 1986;2:533-537.
6. Ridker PM, Vaughan, DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
7. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
8. Di Minno G, Mancini FP, Margaglione M. Hemostatic variables and ischemic cardiovascular disease: do we need a concerted effort for more profitable future clinical investigations? Cardiovasc Drugs Ther. 1996;10:743-749.
9. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller. GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
10. Jansonn JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary heart disease. Circulation. 1993;88:2030-2034.
11. Ridker PM, Vaughan, DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
12. Ridker PM, Hennekens CH, Stampfer MJ, Manson J, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
13. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381-387.
14. Bachmann F. Molecular aspects of plasminogen, plasminogen activators and plasmin. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, eds. Haemostasis and Thrombosis. Edinburgh, Scotland: Churchill Livingstone; 1994:575-614.
15. Pralong G, Calandra T, Glauser MP. Plasminogen activator inhibitor-1: a new prognostic marker in septic shock. Thromb Haemost. 1989;61:459-462.
16. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
17. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44:37-42.
18. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
19. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
20. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
21. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
22. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppress plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation. 1996;93:1073-1078.
23. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Sourbrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounts for half of the variance of serum enzyme levels. J Clin Invest, 1990;86:1343-1346.